Breaking News, Collaborations & Alliances

Merck, JT in Osteo-Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck and Japan Tobacco Inc. (JT) have signed a worldwide licensing agreement to develop and commercialize JTT-305, an investigational oral osteoanabolic (bone growth stimulating) agent for the treatment of osteoporosis. Merck will gain worldwide rights, except for Japan, to develop and commercialize JTT-305. JT will receive an upfront payment and is eligible to receive additional cash payments upon achievement of certain development milestones associated and product royalties. JTT-305 is ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters